Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

  • Caribou Biosciences Inc CRBU announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). 
  • Following a single dose at the initial dose level of 40 million CAR-T cells, a 100% complete response (CR) rate (6 of 6 patients) was observed as the best response. 
  • Related: Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study.
  • At 6 months following the single dose of CB-010, 40% of patients remained in CR (2 of 5 patients) as of the May 13 data cutoff date. 
  • One patient suffered grade 3 immune effector cell-associated neurotoxicity syndrome that resolved in 39 hours. Still, none of the patients experienced graft-versus-host disease or grade 2 or greater cytokine release syndrome (CRS). Two patients had grade 1 CRS. 
  • Caribou has begun enrolling patients at the second dose level, 80 million CAR-T cells. Doubling the dose could drive longer-lasting responses.
  • "Our conviction is intact that the recent dataset positions CRBU to potentially differentiate vs. competitors in a meaningful and favorable way as data matures and the company explores larger patient numbers and higher dose(s)," SVB Securities wrote. 
  • HC Wainwright says that CB-010's response rate and the complete response rate are more competitive than those seen with the FDA-approved CAR-T agents. 
  • It notes that Gilead Sciences Inc's GILD Yescarta demonstrated a 74% ORR (54% CR) and 94% ORR (79% CR) in DLBCL and FL, respectively, and Novartis AG's NVS Kymriah demonstrated a 53% ORR (39% CR) and 87% ORR (68% CR) in DLBCL and FL, respectively.
  • Price Action: CRBU shares are down 25.70% at $5.16 during the market session on the last check Monday.

Posted In: BriefsAnalyst ColorBiotechNewsHealth CareSmall CapAnalyst RatingsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.